Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020
Open Access
- 16 July 2020
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 25 (28), 2-8
- https://doi.org/10.2807/1560-7917.ES.2020.25.28.2001260
Abstract
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.Keywords
This publication has 16 references indexed in Scilit:
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJama-Journal Of The American Medical Association, 2020
- Evaluation of nine commercial SARS-CoV-2 immunoassaysPublished by Cold Spring Harbor Laboratory ,2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their ImplicationsSSRN Electronic Journal, 2020
- Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging CoronavirusesThe Journal of Infectious Diseases, 2013